2019/8/30 World-renowned professional information services company, Clarivate Analytics, released a special report, “Pharmaceutical Innovation in the APAC Region – A Quantitative Company Ranking [...]
About Chang LisaThis author has not yet filled in any details.
So far Chang Lisa has created 38 blog entries.
TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.
2019/1/2 TaiRx, Inc. (6580) announces good news at the start of 2019 that it receives “Technology and Product or Technology Development is Successful [...]
TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance
2018/10/23 TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the [...]
A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.
2018/4/15 TaiRx’s CVM-1118 small molecule cancer drug received US FDA approval on April 15th to conduct multi-nation, multi-center Phase II clinical trial in [...]
A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.
2018/3/8 TaiRx, Inc. (6580) announces today that its new injection product, Zelnite®, received NDA approval from the Taiwan FDA on January 22nd, 2018. [...]
TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.
2017/10/31 Lee WJ, Chen YL, Chu YW, Chien DS. Comparison of glutathione peroxidase-3 protein expression and enzyme bioactivity in normal subjects and patients with sepsis. Clin Chim Acta. [...]
TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.
2017/8/22 TaiRx Announces License Agreement with Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago, for Nodal Patents to Develop [...]
TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.
2017/6/15 TaiRx shows its potential in new cancer drug development and will be listed on the emerging stock market on June 20th. […]
2017/6/5 TaiRx, Inc. (6580) publishes its Phase I clinical trial result in the United States and Taiwan on CVM-1118, a new cancer drug, at [...]
Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer.
2016/06/17 This issue of Science magazine (June 17, 2016) featured a column on how malignant tumor cells avoid traditional anti-angiogenesis mechanism and achieve metastasis. [...]